EORTC/LinkedIn
Jul 16, 2025, 20:36
Latest findings from the EORTC-BTG-1320 trial
European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“Have you seen the latest findings from the EORTC-BTG-1320 trial? This radiological post-hoc analysis explores how different tumour size measurements impact prognosis in recurrent WHO grade 2 and 3 meningiomas.
Key findings:
- Unidimensional and volumetric tumour progression are strongly associated with overall survival.
- Bidimensional tumour measurements are not significantly associated with overall survival.
- These insights could refine radiological monitoring and treatment planning in recurrent meningioma patients.
Discover how advanced imaging metrics could improve prognostic accuracy in neuro-oncology. Read more.”
More posts featuring European Organisation for Research and Treatment of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 13, 2025, 15:48
Aug 13, 2025, 15:36
Aug 13, 2025, 15:30
Aug 13, 2025, 15:29
Aug 13, 2025, 15:25
Aug 13, 2025, 15:15
Aug 13, 2025, 15:14